Every 8-K that Xtant Medical Holdings, Inc. (XTNT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XTNT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XTNT filings page.
Xtant Medical Holdings, Inc. reported weaker results for the quarter ended June 30, 2026. Revenue was $23.0 million, down from $35.4 million a year earlier, mainly due to the sale of Coflex/CoFix and international hardware assets and the non-recurrence of high-margin license revenue tied to Q-code and amniotic membrane agreements.
Gross margin fell to 57.9% from 68.6%, reflecting the loss of high-margin license revenue, reduced production efficiencies, and higher excess and obsolete inventory charges. Operating expenses rose to $22.5 million from $19.7 million, driven by a $5.0 million exclusivity fee related to a new U.S. distribution agreement with Dilon Technologies. The company swung to a net loss of $9.4 million from net income of $3.6 million, and non-GAAP adjusted EBITDA declined to a loss of $2.7 million from positive $6.9 million.
As of June 30, 2026, Xtant held $9.9 million in cash and cash equivalents and $23.0 million of total indebtedness. Management modestly reduced full-year 2026 revenue guidance to $99–$103 million, from $101–$105 million, citing lower-than-expected biologics revenue and ongoing headwinds in its amnio product line. Strategically, Xtant launched Trivium™ Shaped and secured exclusive U.S. rights to Dilon’s HEMOBLAST® Bellows, adding a ~20-person sales team.
Xtant Medical Holdings, Inc. reported voting results from its August 7, 2026 Annual Meeting of Stockholders.
There were 140,262,960 shares of common stock outstanding and entitled to vote as of June 9, 2026. Holders of 104,456,998 shares were present in person or represented by proxy, representing 74.47% of outstanding shares and constituting a quorum.
Stockholders voted on three proposals. For the first proposal, the individuals listed received between 79,590,709 and 80,450,301 votes for, with 23,783,663 broker non-votes recorded. A second proposal received 104,245,812 votes for, 30,112 against and 181,074 abstentions. A third proposal received 79,416,901 votes for, 1,030,090 against, 226,344 abstentions and 23,783,663 broker non-votes.
Xtant Medical Holdings reported first quarter 2026 revenue of $20.9 million, down from $32.9 million a year earlier, mainly due to the December 2025 sale of Coflex/CoFix assets and international hardware, and prior-year license revenue that did not repeat. Gross margin declined to 57.3% from 61.5% as high-margin license revenue ended. Operating expenses fell to $14.9 million from $19.2 million, but the company posted a net loss of $3.1 million versus net income of $58,000 and a non-GAAP adjusted EBITDA loss of $1.6 million versus positive $3.0 million. Xtant strengthened its balance sheet by reducing total indebtedness to $12.2 million from $25.4 million and ended the quarter with $12.2 million in cash and cash equivalents. Management raised full-year 2026 revenue guidance to a range of $101-$105 million, reflecting an exclusive U.S. distribution agreement for Dilon Technologies’ HEMOBLAST Bellows hemostatic product and integration of Dilon’s U.S. sales team.
Xtant Medical Holdings, Inc. has entered into an exclusive U.S. Distribution Agreement with Dilon Technologies, Inc. for the FDA-approved HEMOBLAST® Bellows surgical hemostatic product. Xtant paid Dilon a $5.0 million exclusivity fee, which may be repayable to Xtant if the agreement is terminated under certain conditions.
In connection with the deal, Xtant hired approximately 20 Dilon U.S. sales personnel to support commercialization. Dilon will continue to manufacture HEMOBLAST Bellows in France and supply it to Xtant at a specified transfer price. The companies highlight that HEMOBLAST targets an estimated $2.0 billion global hemostatic market, and Xtant plans to update its full-year 2026 financial guidance when it reports first quarter 2026 results.
Xtant Medical Holdings, Inc. reported a strong turnaround for 2025, shifting to profitability while reshaping its portfolio. Full-year 2025 revenue reached $133.9–$134.0 million, up about 14% from 2024, driven by higher license revenue and growth in its core biologics business.
Net income for 2025 improved to $5.0 million, or $0.03–$0.04 per share, compared with a prior-year net loss of $16.5 million. Non-GAAP adjusted EBITDA rose to $16.3 million from a loss of $2.3 million, reflecting better gross margins of 62.9% and lower operating expenses. Cash and restricted cash increased to $17.3 million at year-end, supported by divesting non-core Coflex/CoFix assets and an international hardware business.
For 2026, the company expects revenue between $95 million and $99 million, as organic growth in higher-margin biologics is offset by the December 2025 divestitures and the end of 2025 license revenue streams. Management highlighted a term loan balance of $11.2 million and a current cash position above $22 million, and it expects to be free cash flow positive in 2026 without raising additional outside capital.
Xtant Medical Holdings, Inc. reported receiving a $10.7 million payment from Companion Spine on February 27, 2026. This payment covered full repayment of an $8.2 million unsecured promissory note, accrued interest, and net working capital and other purchase price adjustments related to prior divestitures.
These divestitures involved certain Coflex and CoFix assets and all shares of Paradigm Spine GmbH and now total an aggregate purchase price of $21.4 million. Xtant used $2.8 million of the proceeds to prepay part of its term loan with MidCap Financial Trust, leaving $11.1 million of principal outstanding.
Xtant Medical Holdings reports an amendment to the financing terms tied to its prior divestitures of the Coflex/CoFix product assets and Paradigm Spine GmbH to Companion Spine. The original $17.5 million Coflex/CoFix divestiture included an unsecured promissory note of $8.2 million from Companion Spine, initially due on January 15, 2026. On January 15, 2026, the parties extended this note’s maturity date to January 31, 2026. At the same time, they revised the Paradigm Spine GmbH sale agreement to move payment of the estimated positive purchase price adjustment of $1,742,000 from January 15, 2026 to January 31, 2026, aligning both obligations on the same later date.
Xtant Medical Holdings has completed two divestitures to Companion Spine involving its Coflex/CoFix product assets and its Paradigm Spine GmbH subsidiary. The Coflex/CoFix asset sale carried a total purchase price of $17.5 million, including $7.5 million of prior non‑refundable deposits, $1.8 million of cash at closing, and an $8.2 million unsecured promissory note maturing on January 15, 2026, all subject to an inventory-based adjustment. The Paradigm Spine GmbH equity sale had a total purchase price of $1.7 million, payable in cash and subject to later working-capital and other adjustments that can either increase cash received or reduce the note’s principal.
Under its credit agreement with MidCap Financial Trust, Xtant used approximately $8.0 million of net cash proceeds from these transactions to prepay part of its term loan, leaving $14.4 million outstanding as of December 1, 2025, with up to an additional $1.6 million prepayment required if the Companion Spine note is repaid.
Xtant Medical Holdings (XTNT) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1 and are furnished, not filed, under the Exchange Act.
The company highlighted its use of non‑GAAP adjusted EBITDA, defined as net income (loss) from operations before depreciation and amortization, interest, and taxes, further adjusted for separation‑related expenses, non‑cash compensation, divestiture/acquisition‑related expenses, acquisition‑related fair value adjustments, and unrealized foreign currency translation gains or losses.
Xtant notes that adjustments include expenses tied to its pending divestiture of non‑core Coflex/CoFix assets and its international hardware business. A reconciliation to GAAP metrics appears in the press release.
Xtant Medical Holdings reported results from its November 7, 2025 annual meeting. Stockholders approved an amendment to the 2023 Equity Incentive Plan to increase the shares available under the plan by 12,300,000, effective immediately upon approval.
Shareholders also elected all nominated directors and approved other proposals, including advisory votes on executive compensation and auditor matters. The Board set the say‑on‑pay frequency at one year. A quorum was present with 96,880,348 shares represented, or 69.2% of shares outstanding as of the record date. Shares outstanding were 140,000,485 as of September 9, 2025.
Xtant Medical Holdings, Inc. announced its financial results for the three and six months ended June 30, 2025 and furnished a related press release and investor presentation as exhibits to this Current Report.
The company explained its use of a non-GAAP adjusted EBITDA metric, defined as net income (loss) before depreciation and amortization, interest and tax benefit (expense), and further adjusted to add back or exclude separation-related expenses, non-cash compensation, divestiture/acquisition-related expenses, acquisition-related fair value adjustments, and unrealized foreign currency translation gains or losses. The press release reconciles this non-GAAP measure to GAAP net income. The filing also discloses a pending divestiture of its non-core Coflex/CoFix spinal implants and international business and notes that furnished materials are provided pursuant to Regulation FD.
Xtant Medical Holdings, Inc. established November 7, 2025 as the date for its 2025 Annual Meeting of Stockholders and said it anticipates printing the proxy statement on or about September 12, 2025 and mailing or making it available commencing on or about September 15, 2025. The company noted the meeting date changed by more than 30 days from last year.
Because of that change, stockholder proposals under Rule 14a-8 must be received at the company’s principal executive offices by the close of business on August 18, 2025. Other stockholder proposals and director nominations under the Bylaws also must be delivered in writing to the Corporate Secretary by August 18, 2025. Stockholders seeking to solicit proxies for alternative director nominees must comply with the universal proxy requirements, including providing written notice no later than September 8, 2025.